Thomas A. Abrams, MD of Dana Farber Cancer Institute discusses how checkpoint inhibitors will be used in unresectable HCC treatment at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Checkpoint Inhibitors are Active Agents in HCC
